Vir Biotechnology (VIR) Net Cash Flow (2018 - 2026)

Vir Biotechnology has disclosed Net Cash Flow across 9 years of filings, most recently posting $42.0 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $42.0 million, down 14.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$85.0 million (down 145.3% YoY), and the FY2025 annual result was -$77.6 million, down 235.23% from the prior year.
• Net Cash Flow came in at $42.0 million for Q1 2026 at Vir Biotechnology, down from $61.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $690.9 million in Q2 2022 to a low of -$542.7 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$52.8 million (2024), against an average of -$4.7 million.
• Peak annual rise in Net Cash Flow reached 452.44% in 2022, while the deepest fall reached 1816.04% in 2022.
• Vir Biotechnology's Net Cash Flow stood at -$116.0 million in 2022, then plunged by 81.95% to -$211.1 million in 2023, then jumped by 125.76% to $54.4 million in 2024, then rose by 13.7% to $61.8 million in 2025, then slumped by 32.1% to $42.0 million in 2026.
• The last three Net Cash Flow figures came in at $42.0 million (Q1 2026), $61.8 million (Q4 2025), and -$127.0 million (Q3 2025), per Business Quant data.